Evidence Hub

Successful sequential therapy for Stenotrophomonas maltophilia infection in a preterm neonate: a case report

Nahari M, Alaboud M, Mohinuddin S, Faden M, Balhareth Y, Alsaleem N

Frontiers in pediatrics, 2025

1 citation

Abstract

Background: A multidrug-resistant pathogen increasingly seen in newborn intensive care units, stenotrophomonas maltophilia presents treatment difficulties for preterm babies.

Case presentation: A 28-week preterm neonate developed S. maltophilia sepsis following prolonged mechanical ventilation. Initial therapy with trimethoprim- sulfamethoxazole (TMP-SMX) was ineffective, prompting a switch to levofloxacin, which led to clinical recovery and infection clearance.

Conclusion: This case highlights the need for tailored antimicrobial strategies in neonatal S. maltophilia infections. Sequential therapy with TMP-SMX and levofloxacin was effective, supporting the judicious use of fluoroquinolones in resistant cases.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free